CHROMOGENICS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.48 SEK | -6.09% |
|
-4.71% | -7.43% |
| 04-02 | ChromoGenics AB Receives First Order for North America | CI |
| 03-08 | ChromoGenics AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Construction Supplies & Fixtures
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -7.43% | 4.27M | - | ||
| +35.22% | 8.33B | B+ | ||
| +11.00% | 2.5B | D+ | ||
| +19.17% | 1.16B | B | ||
| +17.54% | 796M | - | ||
| +1.80% | 416M | - | - | |
| +2.85% | 357M | - | - | |
| +6.28% | 229M | - | - | |
| +14.62% | 203M | - | - | |
| -0.85% | 165M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CHRO Stock
- Ratings ChromoGenics AB
